Peptides & Peptide Pools for Cancer Immunotherapy Research

2026-03-04

Peptides & Peptide Pools for Cancer Immunotherapy Research

Featuring PRAME – A High-Value Immuno-Oncology Target

PRAME peptide pools are commonly used for:

・Antigen-specific T cell activation and expansion
・Epitope screening and HLA-restricted peptide studies
・TCR-T and TIL immunotherapy research
・Cancer vaccine development and immune monitoring

► Download Flyer (PDF)

Key Highlights：

PRAME: A High-Value Cancer-Testis Antigen

• Preferentially expressed in tumors
• Minimal expression in normal tissues
• Validated in TCR-T, TIL and vaccine research

Why PRAME?
Melanoma,AML,NSCLC,Breast & Ovarian Cancer

When should you use PRAME peptide pools in immunotherapy studies?

PRAME (Preferentially Expressed Antigen in Melanoma) is a well-known cancer-testis antigen (CTA) widely studied as a target for T cell–based cancer immunotherapy. Because PRAME is preferentially expressed in tumors while showing minimal expression in normal tissues, PRAME peptides are frequently used in immuno-oncology research.

CROYEZ Peptide Solutions Supporting Translational Immunotherapy Research

Ready-to-Use Research Tools	Custom Peptide Design Services	Research Applications We Support
PRAME peptide pools HLA-A02 / A24 / A03 restricted epitopes MHC-I & MHC-II design Validated targets for TIL & TCR research	Sequence-specific synthesis HLA-matched epitope design MHC-I & MHC-II restricted peptides Flexible scale & purity options Fast turnaround & global delivery	Antigen-specific T cell expansion Epitope screening & validation Immune response monitoring Vaccine development Preclinical & translational studies

Further Reading from the Original Manufacturer：For additional background on PRAME as a cancer-testis antigen and the mechanisms of T cell recognition, please refer to the following resources from Peptides & Elephants:
• PRAME – Cancer-Testis Antigen Overview
• T Cell Recognition and Co-Receptor Function (MHC I vs MHC II)

Back to List